PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT

• Status: Completed
• Trial end date: 2021-05-01
• Target enrollment: 0
• Participant gender: All

Summary

All patients received Flu-BU-VP16 as myeloablative conditioning followed by cyclophosphamide (D+3 and +4) and subsequent tacrolimus. For patients with unrelated or haplo-donor received low-dose ATG at Day +15.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Criteria

Inclusion Criteria:

• patients with lymphoid malignancies: CR1 or CR2 for acute lymphoblastic leukemia; T cell lymphoma (any CR/PR); B cell lymphoma (PR1 or CR2), hodgkin's disease (CR2 or beyond), Sezary syndrome

• patients with HLA matched sibling, unrelated (HLA 9~10/10 matched) or haplo-identical donor

Exclusion Criteria:

• patients with active infection

• patients with abnormal liver function damage: ALT/AST above 2X normal range

• patients with abnormal renal function damage Scr>160µmol/L;

• patients with insufficient pulmonary function (FEV1，FVC，DLCO<50%）and heart failure or with EF <50%)

• patients with mental instability

• unwilling to give inform consent